title: Merkel cell carcinoma developing after antithymocyte globulin and cyclosporine therapy for aplastic anemia.
abstract: We report a patient who developed Merkel cell carcinoma (MCC) after treatment with antithymocyte globulin and cyclosporine for aplastic anemia. The clinical course was progressive and poor prognosis. Although MCC is relatively rare in second cancers arising after immunosuppressive therapy, patients should be closely monitored for the development of this complication as well as other second malignancies.
authors.affiliation: Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan. t-maki@swim.seaple.icc.ne.jp
authors.forename: Maki
authors.initials: M
authors.lastname: Takabayashi
authors.forename: Rika
authors.initials: R
authors.lastname: Sakai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakamoto
authors.forename: Youichi
authors.initials: Y
authors.lastname: Iemoto
authors.forename: Heiwa
authors.initials: H
authors.lastname: Kanamori
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Inayama
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000368:Aged; D000741:Anemia, Aplastic / Q000188:drug therapy*; D000961:Antilymphocyte Serum / Q000009:adverse effects* / Q000627:therapeutic use; D015266:Carcinoma, Merkel Cell / Q000139:chemically induced*; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine